AJTMH Transactions of the Royal Society of Tropical Medicine and Hygiene
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am. J. Trop. Med. Hyg., 73(5), 2005, pp. 826-832
Copyright © 2005 by The American Society of Tropical Medicine and Hygiene

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (13)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by ZONGO, I.
Right arrow Articles by ROSENTHAL, P. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by ZONGO, I.
Right arrow Articles by ROSENTHAL, P. J.
Related Collections
Right arrow Drug-Resistance
Right arrow Malaria

AMODIAQUINE, SULFADOXINE-PYRIMETHAMINE, AND COMBINATION THERAPY FOR UNCOMPLICATED FALCIPARUM MALARIA: A RANDOMIZED CONTROLLED TRIAL FROM BURKINA FASO

ISSAKA ZONGO, GRANT DORSEY, NOEL ROUAMBA, CHRISTIAN DOKOMAJILAR, MOISE LANKOANDE, JEAN-BOSCO OUEDRAOGO, AND PHILIP J. ROSENTHAL*
Institut de Recherche en Science de la Santé, Bobo-Dioulasso, Burkina Faso; University of California, San Francisco, California

Increasing resistance to chloroquine necessitates the evaluation of other antimalarial therapies in Africa. We compared the efficacies of amodiaquine (AQ), sulfadoxine-pyrimethamine (SP), and AQ + SP for the treatment of uncomplicated falciparum malaria in a randomized trial of patients 6 months of age or older in Bobo-Dioulasso, Burkina Faso. Of the 944 patients enrolled, 829 (88%; 53% under 5 years of age) were assigned 28-day efficacy outcomes. For all regimens, early treatment failures were uncommon (< 2%). Considering all treatment failures based on WHO criteria, AQ + SP was most efficacious (failures in 4.2%), followed by SP (9.1%) and AQ (17.9%; P < 0.02 for all pairwise comparisons). Considering only clinical failures, relative efficacies were similar (failures in 2.1% with AQ + SP, 6.5% with SP, and 13.2% with AQ; P < 0.02 for all pairwise comparisons). The risk of recrudescence was lower with AQ + SP (2.1%) compared with SP (6.1%, P = 0.02) and AQ (8.1%, P = 0.001). Risks of new infection were lower with AQ + SP (2.1%) and SP (2.4%) compared with AQ (9.1%, P < 0.001 for both comparisons). No serious adverse events were seen. AQ + SP appears to offer a highly effective, inexpensive, and available therapy for the treatment of uncomplicated malaria in Burkina Faso.


Received April 20, 2005. Accepted for publication June 6, 2005.

Acknowledgments: The authors thank the clinical study teams in the dispensaries of Colsama (Minata Yampa, Christine Ouaro Sylvain Zoundi), Sarlafao (Georgette Dabire, Gneme Moumouni), and Ouezzin-Ville (Yolande Sanou, Korotoumou Sontie, Aissiata Boly) and the laboratory technicians (Patrice Hien, Adama Sankara, Daouda Traore, San Coulibaly, Mahamoudou Minoungou). We also thank Assobga Franck Godefroy, Harouna Zigani, and Halidou Tinto for assistance with data entry and Heidi Hopkins for assistance in protocol preparation.

Financial support: This work was supported by grant D43 TW01506 from the Fogarty International Center of the National Institutes of Health.

* Address correspondence to Philip J. Rosenthal, Box 0811, University of California, San Francisco, CA 94143. E-mail: rosnthl{at}itsa.ucsf.edu

Authors’ addresses: Issaka Zongo, Noel Rouamba, Moise Lankoande, and Jean-Bosco Ouedraogo, Institut de Recherche en Sciences de la Santé, Bobo-Dioulasso, Burkina Faso. Grant Dorsey, Christian Dokomajilar, and Philip J. Rosenthal, Box 0811, University of California, San Francisco, CA 94143.

Reprint requests: Philip J. Rosenthal, Box 0811, University of California, San Francisco, CA 94143, Telephone: 1-415-206-8845, Fax: 1-415-648-8425, E-mail: rosnthl{at}itsa.ucsf.edu.




This article has been cited by other articles:


Home page
Antimicrob. Agents Chemother.Home page
B. Greenhouse, C. Dokomajilar, A. Hubbard, P. J. Rosenthal, and G. Dorsey
Impact of Transmission Intensity on the Accuracy of Genotyping To Distinguish Recrudescence from New Infection in Antimalarial Clinical Trials
Antimicrob. Agents Chemother., September 1, 2007; 51(9): 3096 - 3103.
[Abstract] [Full Text] [PDF]


Home page
Am J Trop Med HygHome page
A. Sowunmi, G. O. Gbotosho, C. T. Happi, A. A. Adedeji, F. A. Fehintola, O. A. Folarin, E. Tambo, and B. A. Fateye
Therapeutic Efficacy and Effects of Artemether-Lumefantrine and Amodiaquine-Sulfalene-Pyrimethamine on Gametocyte Carriage in Children with Uncomplicated Plasmodium falciparum Malaria in Southwestern Nigeria
Am J Trop Med Hyg, August 1, 2007; 77(2): 235 - 241.
[Abstract] [Full Text] [PDF]


Home page
Am J Trop Med HygHome page
B. GREENHOUSE, A. MYRICK, C. DOKOMAJILAR, J. M. WOO, E. J. CARLSON, P. J. ROSENTHAL, and G. DORSEY
VALIDATION OF MICROSATELLITE MARKERS FOR USE IN GENOTYPING POLYCLONAL PLASMODIUM FALCIPARUM INFECTIONS
Am J Trop Med Hyg, November 1, 2006; 75(5): 836 - 842.
[Abstract] [Full Text] [PDF]


Home page
Am J Trop Med HygHome page
C. DOKOMAJILAR, Z. M. LANKOANDE, G. DORSEY, I. ZONGO, J.-B. OUEDRAOGO, and P. J. ROSENTHAL
Roles of specific Plasmodium falciparum mutations in resistance to amodiaquine and sulfadoxine-pyrimethamine in burkina faso.
Am J Trop Med Hyg, July 1, 2006; 75(1): 162 - 165.
[Abstract] [Full Text] [PDF]


Home page
Am J Trop Med HygHome page
S. R. MESHNICK and A. P. ALKER
AMODIAQUINE AND COMBINATION CHEMOTHERAPY FOR MALARIA
Am J Trop Med Hyg, November 1, 2005; 73(5): 821 - 823.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by the American Society of Tropical Medicine and Hygiene.